Unparalleled biopharmaceutical innovation
Aprogen, founded in 2000 and headquartered in Seongnam, South Korea, is a biopharmaceutical company focused on biosimilar development and manufacturing. The company developed South Korea's first approved antibody biosimilar in 2006 and has since expanded its pipeline to include biosimilars for infliximab, trastuzumab, adalimumab, rituximab, and cetuximab, as well as novel bispecific antibody therapeutics. Aprogen is listed on the KOSPI exchange.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2026
May 2019
Jul 2012
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
